PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Metabolic Syndrome as a Multifaceted Risk Factor for Oxidative Stress

Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials

Frontiers Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference - Canadian Journal of Cardiology

Statin Therapy in Acute Coronary Syndromes Arteriosclerosis, Thrombosis, and Vascular Biology

Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?, Intensive Care Medicine Experimental

Diabetic dyslipidaemia - ScienceDirect

Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle‐related side‐effects - Sivashanmugarajah - 2019 - Internal Medicine Journal - Wiley Online Library

Statin Myopathy.pdf

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet

PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Cholesterol Lowering Drugs - Endotext - NCBI Bookshelf

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Full article: Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management